Search Results
The product title you are looking for is no longer available. Other similar products that may interest you are listed below:
 |
Results for 'Beyond the Blockbuster Drug' |
| Title | Publication Date | Price | Relevance |
|---|---|---|---|
|
Currently Druggable in Prostate Cancer A Drug Target Competitive Analysis |
September 2008 | £1700 | 42.5 % |
|
Currently Druggable in Breast Cancer A Drug Target Competitive Analysis |
August 2008 | £1700 | 42.5 % |
|
GSK's Cervarix A Future Blockbuster of 2007 |
March 2007 | £1999 | 41.5 % |
|
Currently Druggable in Colorectal Cancer A Drug Target Competitive Analysis |
December 2008 | £1700 | 41.5 % |
|
Cancer Antibodies: Competitive Positioning for Success |
June 2008 | £1700 | 41.5 % |
|
Cancer Antibodies Competitive Positioning for Success |
June 2008 | £1700 | 41.5 % |
|
Cancer Vaccines: Aim and Shoot |
May 2008 | £1700 | 40.5 % |
|
Blockbuster Pharmaceutical Launches Establishing Market Leadership |
May 2006 | £2095 | 40.5 % |
|
Currently Druggable in Melanoma A Drug Target Competitive Analysis |
October 2008 | £1700 | 35.5 % |
|
Pharmaceutical Market Trends, 2008 - 2012 Key market forecasts and growth opportunities (3rd Edition) |
November 2008 | £1350 | 35 % |
|
Flomax Case Study Evolving Disease State Awareness to Succeed with New Method of Action |
July 2008 | £2110 | 34.5 % |
|
The Global Pain Market 2008-2023 |
November 2008 | £1499 | 34.5 % |
|
Commercial Insight: CNS Market Overview Commercial dynamics and outlook of the neurology, pain and psychiatry market sectors |
April 2008 | £8000 | 34 % |
|
Pipeline and Commercial Insight: Alzheimer's Disease Scenario Forecasts Reveal Vast Market Potential |
March 2008 | £7600 | 34 % |
|
Pipeline Insight: Orphan Diseases in CNS - Part I: Huntington's Disease |
November 2007 | £3800 | 32.5 % |
|
Shire plc: PharmaVitae Profile |
November 2008 | £3010 | 32 % |
|
From Idea to Market: Product Lifecycle Management in the Pharmaceutical Industry (Market Focus) |
July 2007 | £1000 | 31.85 % |
|
Exubera Case Study Misjudging The Market |
July 2008 | £1760 | 31.85 % |
|
U.S. Market for Gastrointestinal Pharmaceuticals |
September 2005 | £3085 | 31 % |
|
Generic Drug Market in Canada |
August 2009 | £765 | 29.5 % |
|
Pharmaceutical Industry Dynamics and Information Strategy |
August 2005 | £1945 | 29.4 % |
|
From blockbuster to nichebuster Niche therapies drive future drugs growth and incentivize R&D investment over sales spending |
July 2006 | £1055 | 28.7 % |
|
Pipeline Insight: Hepatitis C Protease inhibitors to drive market expansion |
June 2006 | £6495 | 28.5 % |
|
The Pharmaceutical Industry 2008 Current and Future Trends and Strategic Issues Shaping Pharma |
March 2008 | £3010 | 27.5 % |
|
The Rise of Mid-Sized Pharma What makes mid-sized companies successful – and what big Pharma can learn from them? |
May 2008 | £795 | 27 % |
|
Small & Specialty Drug Branding Tapping Niche Market Potential |
May 2006 | £2095 | 27 % |
|
Pharmaceutical New Product Commercialization Preparing The Market for Success |
July 2008 | £3240 | 26.5 % |
|
Indication Expansion Opportunities for successful lifecycle management |
March 2007 | £1495 | 26 % |
|
Generics Threats and Opportunities Mounting an Effective Defense Strategy |
June 2008 | £495 | 25 % |
|
Virtual Pharma The Radical Route To Success |
September 2008 | £795 | 24.5 % |
|
Market Development in Anti-virals What is Next? |
August 2004 | £430 | 24.5 % |
|
Centocor, Inc. - SWOT Analysis |
October 2008 | £66 | 24 % |
|
Drug Repositioning A market analysis |
March 2006 | £1095 | 23.5 % |
|
Pre-Launch Planning Priming Your Pharmaceutical Brand for Profit and Success |
November 2008 | £997 | 23.5 % |
|
CNS Market Trends, 2007 to 2010 Key Market Forecasts and Growth Opportunities |
June 2007 | £995 | 23 % |
|
Falling Margins in Pharma - increasing ROI through CRM (Market Focus) |
July 2007 | £1000 | 22.4 % |
|
Inflammatory Directions Strategies for Six Diseases with Unmet Needs |
April 2008 | £715 | 22 % |
|
Ophthalmic Pharmaceuticals, Market Analysis, Forecasts and Dynamics 2009-2023 |
January 2009 | £1499 | 21 % |
|
Commercial Insight: Antihormonal Therapy Cancer Brands Careful Lifecycle Management Needed to Preserve Brand Dominance |
August 2008 | £7600 | 20.3 % |
|
Pipeline Insight: Upper GI Disorders - Generics will limit pipeline profit |
July 2007 | £6000 | 20 % |
|
China Pharmaceutical Chain Industry Report, 2006 |
August 2006 | £955 | 19.95 % |
|
The Global HIV/Aids Market Outlook To 2012 |
July 2007 | £1495 | 19.6 % |
|
Forecast Insight: Insomnia Orexin and serotonin receptor modulators to innovate market |
August 2008 | £7600 | 19.5 % |
|
Pipeline Insight: Non-insulin Antidiabetics Type 2 diabetes unlikely to develop into a switch market |
August 2006 | £6495 | 19.5 % |
|
Eli Lilly Pipeline, Products,Performance,Potential |
March 2008 | £595 | 19.5 % |
|
Antiageing and Life Enhancement Pharmacotherapeutics |
January 2006 | £795 | 19.5 % |
|
CNS Drug Discoveries: Multiple Sclerosis |
November 2006 | £795 | 19.5 % |
|
Pipeline/Commercial Insight: Molecular Targeted Cancer Therapies More drugs on the market, more targets in the pipeline |
October 2006 | £8000 | 19 % |
|
The Handbook on Alliances & Deals in Biotech Business |
May 2004 | £430 | 19 % |
|
Global Antivirals Market Analysis & Forecasts 2008-2023 |
September 2008 | £1499 | 19 % |
|
Stakeholder Insight: Chronic Leukemias Is there room left for improvement? |
November 2008 | £8000 | 19 % |
|
Anti Addiction Therapies, 2006-2011- The Pharmaceutical Industry's Next Viagra? |
October 2006 | £1499 | 19 % |
|
The Antipsychotics Market Insight & Analysis 2008 |
February 2008 | £1499 | 18.9 % |
|
Antipsychotics Market Insight & Analysis 2008 |
February 2008 | £1499 | 18.9 % |
|
Clinical Trials Market 2006, The |
February 2006 | £1499 | 18.5 % |
|
Top 10 Biotech Companies Market Outlook, 2008-2023 |
December 2008 | £1499 | 18.5 % |
|
The Future of Targeted Therapeutics Key Technologies, New Therapy Area Applications and Leading Players |
March 2008 | £1995 | 18.2 % |
|
Canada Pharmaceuticals and Healthcare Report Q3 2007 |
January 2009 | £250 | 18 % |
|
The Autoimmune Outlook to 2013 Competitive landscape, pipeline analysis and growth opportunities |
April 2009 | £2025 | 18 % |
|
Innovations in CNS Novel therapeutics and future R&D strategies |
January 2007 | £1495 | 17.85 % |
|
Commercial Insight: Cytotoxic Therapy Cancer Brands Looming Patent Expiries Limit Market Growth |
July 2008 | £7600 | 17.85 % |
|
Cancer Market Trends 2008 - 2012 Key market forecasts and growth opportunities |
January 2009 | £1100 | 17.5 % |
|
World Asthma and COPD Treatment Market, 2006-2011, The A Changing Market with Increasing Potential |
September 2006 | £1499 | 17.5 % |
|
Stakeholder Opinion: Erectile Dysfunction Identifying product differentiation and patient segmentation strategies |
December 2006 | £2005 | 17.5 % |
|
Global Pharmaceutical Market Forecast to 2012 |
October 2008 | £1145 | 17.5 % |
|
AMD Market Outlook to 2012 |
March 2007 | £1299 | 17.15 % |
|
The Global Anti-Infectives Market Outlook to 2011 |
June 2007 | £1495 | 17.15 % |
|
Teva Pharmaceutical Industries Limited - Financial and Strategic Analysis Review |
July 2009 | £80 | 16.8 % |
|
Biosimilars and Follow-On Biologics Report The Global Outlook 2009-2024 |
April 2009 | £1499 | 16.45 % |
|
Rimonabant: The first of the Cannabinoid blockbusters |
June 2007 | £1499 | 15.75 % |
|
Commercial Insight: Antihormonal Cancer Therapies |
July 2009 | £15200 | 15.75 % |
|
World market for cancer vaccines 2007-2012 |
January 2007 | £1999 | 15.5 % |
|
World Respiratory Disorders Market 2009-2024 |
June 2009 | £1499 | 15.4 % |
|
Antibiotic R&D Resolving the Paradox between Unmet Medical Need and Commercial Incentive |
July 2008 | £2385 | 15.4 % |
|
Pharmaceutical Pricing And Reimbursement Strategies For Market Access Across The Us, Europe, Japan And Other Key Geographies |
November 2007 | £1495 | 15.4 % |
|
Product Lifecycle Management, 2006 |
May 2006 | £1499 | 15.05 % |
|
Prostate Cancer Drug Discoveries What The Future Holds |
November 2009 | £1295 | 15 % |
|
United States Pharmaceuticals and Healthcare Report Q3 2006 |
July 2006 | £395 | 15 % |
|
World Market for Addiction Disorders, 2009 - 2016 The Future Therapies for Substance Dependence and Impulse Control |
October 2009 | £1495 | 15 % |
|
Pricing and Reimbursement in the US Innovation and robust pharmacoeconomic analysis are ke |
June 2006 | £6495 | 14.7 % |
|
Parallel Trade US Lawmakers Allow Imported Prescriptions Drugs |
June 2007 | £1499 | 14.7 % |
|
Healthcare in a Recession (OTC, Generics, Out of Pocket Spending, Healthcare Legislation, Retail Clinics, Outsourcing and Other Topics) |
March 2003 | £1270 | 14.7 % |
|
Herbal Supplements, Prescription Drugs, Rx-to-OTC Products A Comparison |
October 2006 | £3085 | 14.35 % |
|
World Gastrointestinal Disorders Market 2008-2023 |
October 2008 | £1499 | 14.35 % |
|
World Diabetes Market, The 2005-2011 |
March 2006 | £1499 | 13.65 % |
|
Streamlining Information in the Pharmaceutical Industry with PLM (Review Report) |
August 2007 | £1795 | 13.65 % |
|
Innovative And Targeted Cancer Therapies Key Technologies, New Applications And Leading Players |
July 2007 | £1495 | 13.5 % |
|
Emerging Generic Drug Markets in Europe |
December 2007 | £795 | 13.5 % |
|
Japanese Pharmaceutical Market 2008-2023, the |
October 2008 | £1499 | 13.3 % |
|
Abbott Laboratories: PharmaVitae Profile Healthcare |
September 2009 | £5700 | 13.3 % |
|
Gastrointestinal Disorders Market Intelligence to 2012 |
May 2007 | £1499 | 13.3 % |
|
World Generics Market, 2008-2013 |
November 2008 | £1499 | 12.95 % |
|
Bioinformatics Technical Status and Market Prospects |
August 2005 | £3085 | 12.95 % |
|
Indian Pharmaceutical Industry, The: |
March 2005 | £3335 | 12.6 % |
|
Global Ophthalmic Market Analysis & Forecasts to 2012 |
April 2007 | £1499 | 12.6 % |
|
Commercial Insight: Antibacterials Growth in resistance rates drives niche indications |
December 2006 | £8000 | 12.6 % |
|
Pipeline Insight: HIV Extending treatment options |
September 2006 | £6000 | 12.6 % |
|
Commercial Insight Antibacterials Growth in resistance rates drives niche indications |
January 2007 | £8000 | 12.6 % |
|
Launch Strategies - Analyzing Market Trends and Regulatory Impacts |
August 2007 | £8010 | 12.25 % |
|
Biotech 2010 |
June 2006 | £3085 | 12.25 % |
|
Bringing Drugs to Market The role of CRM in improving sales & marketing (Review Report) |
August 2007 | £1000 | 12.25 % |
|
Colorectal Cancer: Pipeline/Commercial Insight Shaping the future dynamics of colorectal cancer management |
October 2006 | £8000 | 12.25 % |
|
Monoclonal Antibody Therapeutics 2009-2024 |
August 2009 | £1499 | 11.9 % |
|
Booming US Generic Drug Market |
August 2009 | £765 | 11.9 % |
|
Strategic Perspectives: Antidyslipidemics Current market is not conducive for growth |
October 2008 | £8000 | 11.9 % |
|
Pipeline Insight: Depression Novel drugs to grow third-line market |
March 2007 | £6000 | 11.55 % |
|
Live-Licensing & In-life Testing R&D Processes and Regulation for New Drugs, 2008-2020 |
January 2008 | £1499 | 11.55 % |
|
Pharmaceutical Pricing, Reimbursement and Parallel Trade 2006 |
March 2006 | £1270 | 11.55 % |
|
Big Pharma's Key Lifecycle Management Strategies Maximizing The Market Potential |
February 2010 | £2230 | 11.55 % |
|
The Global Multiple Sclerosis Market 2009-2024 |
March 2009 | £1499 | 11.2 % |
|
Pharmaceutical Outsourcing Opportunities Post-Launch Contract Manufacturing and Contract Sales and Marketing, 3rd Edition |
January 2009 | £2230 | 11.2 % |
|
Anti-Obesity Treatments Analysis & Forecasts 2009-2024 |
February 2009 | £1499 | 11.2 % |
|
Pharmaceutical Contract Manufacturing Global Market Trends |
November 2009 | £1905 | 10.85 % |
|
Pipeline Insight: Hematological Malignancies Companies target niche indications to facilitate market entry |
April 2009 | £6000 | 10.5 % |
|
The World Dermatological Market Outlook 2010-2024 |
November 2009 | £1499 | 10.5 % |
|
World Generics Market 2006-2011; The |
May 2006 | £1499 | 10.5 % |
|
Commercial Insight: Pain Market Overview Non-Traditional Analgesics and Opioid Reformulations to Sustain Sector Growth |
October 2008 | £8000 | 10.5 % |
|
Outsourcing Clinical Trials A Global Analytical Guide and Comparative Analysis of International Destinations, with Location Attractiveness Index |
May 2007 | £1910 | 10.5 % |
|
World Contract Research and Manufacturing Market, 2006-2011, The Trends in Outsourcing |
August 2006 | £1499 | 10.5 % |
|
Global Smoking Cessation Market Analysis & Forecasts Preparing For The First Blockbuster |
July 2007 | £1499 | 10.15 % |
|
Infectious Diseases Drugs Markets |
October 2009 | £2165 | 10.15 % |
|
World Gastrointestinal Disorders Market 2006-2011; The |
January 2006 | £1799 | 9.8 % |
|
Pipeline Insight: Osteoarthritis The Wait for a DMOAD Continues |
November 2006 | £6000 | 9.8 % |
|
Clinical Trials: World Market 2009-2024 |
July 2009 | £1499 | 9.8 % |
|
Pipeline Insight: Asthma/COPD Targeted therapies on the horizon |
November 2006 | £6000 | 9.8 % |
|
Global Vaccine Market Outlook (2007-2010) |
June 2007 | £1020 | 9.45 % |
|
Neurodegenerative Disease Drug Market Analysis and Forecasts 2007 |
June 2007 | £1999 | 9.45 % |
|
Drug Treatments for Leading Endocrine and Metabolic Diseases |
February 2007 | £3085 | 9.45 % |
|
The US Pharmaceutical Market 2009-2024 |
November 2009 | £1499 | 9.45 % |
|
Pipeline And Commercial Insight Pediatric And Adolescent Vaccines |
July 2007 | £8000 | 9.45 % |
|
Pricing & Reimbursement in Europe Can the drive for cost effectiveness overcome cost containment? |
October 2006 | £6000 | 9.1 % |
|
Global Biotech Market Analysis and Forecasts, 2008-2023 |
August 2008 | £1499 | 8.75 % |
|
Commercial Insight: Cardiovascular market overview Raft of patent expires threaten blockbusters |
October 2007 | £7600 | 8.75 % |
|
Pfizer Market Outlook for a Global Leader, 2008-2013 |
August 2008 | £1499 | 8.75 % |
|
In Vitro Diagnostics Market Report & Analysis 2008-2023 |
June 2008 | £1499 | 8.75 % |
|
Johnson & Johnson: PharmaVitae Profile Healthcare |
July 2009 | £5700 | 8.75 % |
|
World Diabetes Market Analysis 2009-2023 |
February 2009 | £1499 | 8.4 % |
|
World Vaccines Market 2008-2013 Future Forecast, Critical Trends and Developments |
April 2009 | £325 | 8.4 % |
|
Johnson & Johnson PharmaVitae Profile |
July 2008 | £3010 | 8.4 % |
|
Anti-Obesity Treatments 2007-2012 - A blockbuster target market |
July 2007 | £1799 | 8.05 % |
|
Practical Guide to Finding Partners in Pharma and Biotech 2nd edition |
April 2009 | £695 | 7.5 % |
|
Commercial Insight: Asthma & COPD Combination Products Still Have Blockbuster Potential |
July 2007 | £7600 | 7.35 % |
|
PAREXEL's Bio/Pharma R&D Statistical Sourcebook 2009 / 2010 |
June 2009 | £270 | 7 % |
|
Parexel's Pharmaceutical R&D Statistical Sourcebook 2007/2008 |
May 2007 | £270 | 7 % |
|
M&A trends in Pharma |
October 2008 | £6000 | 7 % |
|
New Dynamics and Challenges in The Generics Market 2007 |
January 2007 | £1870 | 6.65 % |
|
Immunotherapy of Cancer |
March 2007 | £3085 | 6.3 % |
|
Oncology Market Leaders Analyses and Outlook, Market Report 2008 - 2023 |
October 2008 | £1499 | 5.95 % |
|
Generic League Market Analysis and Forecasts, 2007-2012, 2017 & 2022 |
February 2008 | £1999 | 5.25 % |
